ReviewPharmaceutics2023
In Vitro Dissolution and Permeability Testing of Inhalation Products: Challenges and Advances.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- A Single Dose, Randomized, Open-Label, Cross-Over Bioequivalence Study of Budesonide Pressurized Metered-Dose Inhaler in Healthy Chinese Subjects.Pharmacology research & perspectives · 2025Trial
- Chromatographic Characterization of Nasal and Inhalation Drug Products: A Review of Liquid Chromatography Strategies for Formulation Assessment, Particle Size Correlation, and In Vitro Performance Testing.Biomedical chromatography : BMC · 2026Review
- Simulation of drug transport in airway surface liquid considering mucus flow and ciliary interaction.Scientific reports · 2025Article
- iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug Products.Molecular pharmaceutics · 2025Review
- An In Vitro Dissolution Method for Inhaled Drugs Depositing in the Tracheobronchial Lung Region.Pharmaceutical research · 2025Article
- Advanced Manufacturing Methods for High-Dose Inhalable Powders.Pharmaceutics · 2025Review
- Development of a biorelevant dissolution method for inhalation products: Proof of concept using drugs with diverse solubilities.ADMET & DMPK · 2025Article
- Clinically Relevant Characterization and Comparison of Ryaltris and Other Anti-Allergic Nasal Sprays.Pharmaceutics · 2024Article
- A Novel Combined Dry Powder Inhaler Comprising Nanosized Ketoprofen-Embedded Mannitol-Coated Microparticles for Pulmonary Inflammations: Development, In Vitro-In Silico Characterization, and Cell Line Evaluation.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Inhalation Dosage Forms: A Focus on Dry Powder Inhalers and Their Advancements.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Carrier-Free Inhalable Dry Microparticles of Celecoxib: Use of the Electrospraying Technique.Biomedicines · 2023Article
- Green Routes for Bio-Fabrication in Biomedical and Pharmaceutical Applications.Pharmaceutics · 2023Review
- Cancer-associated mesenchymal stem/stromal cells: role in progression and potential targets for therapeutic approaches.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vitro dissolution and permeability testing aid the simulation of the in vivo behavior of inhalation drug products. Although the regulatory bodies have specific guidelines for the dissolution of orally administered dosage forms (e.g., tablets and capsules), this is not the case for orally inhaled formulations, as there is no commonly accepted test for assessing their dissolution pattern. Up until a few years ago, there was no consensus that assessing the dissolution of orally inhaled drugs is a key factor in the assessment of orally inhaled products. With the advancement of research in the field of dissolution methods for orally inhaled products and a focus on systemic delivery of new, poorly water-soluble drugs at higher therapeutic doses, an evaluation of dissolution kinetics is proving crucial. Dissolution and permeability testing can determine the differences between the developed formulations and the innovator's formulations and serve as a useful tool in correlating in vitro and in vivo studies. The current review highlights recent advances in the dissolution and permeability testing of inhalation products and their limitations, including recent cell-based technology. Although a few new dissolution and permeability testing methods have been established that have varying degrees of complexity, none have emerged as the standard method of choice. The review discusses the challenges of establishing methods that can closely simulate the in vivo absorption of drugs. It provides practical insights into method development for various dissolution testing scenarios and challenges with dose collection and particle deposition from inhalation devices for dissolution tests. Furthermore, dissolution kinetic models and statistical tests to compare the dissolution profiles of test and reference products are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.